Surrogate End Points for Clinical Trials of Kidney Disease Progression
- 1 July 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 1 (4) , 874-884
- https://doi.org/10.2215/cjn.00600206
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Shared parameter models for the joint analysis of longitudinal data and event timesStatistics in Medicine, 2005
- Improved estimation of controlled direct effects in the presence of unmeasured confounding of intermediate variablesStatistics in Medicine, 2005
- The association between atherosclerotic risk factors and renal function in the general populationKidney International, 2005
- Diabetic Nephropathy: The Proteinuria HypothesisAmerican Journal of Nephrology, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care OrganizationArchives of internal medicine (1960), 2004
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuriaThe Lancet, 1999
- Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathyKidney International, 1996
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992